[go: up one dir, main page]

EP1356053A2 - Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide - Google Patents

Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide

Info

Publication number
EP1356053A2
EP1356053A2 EP02718823A EP02718823A EP1356053A2 EP 1356053 A2 EP1356053 A2 EP 1356053A2 EP 02718823 A EP02718823 A EP 02718823A EP 02718823 A EP02718823 A EP 02718823A EP 1356053 A2 EP1356053 A2 EP 1356053A2
Authority
EP
European Patent Office
Prior art keywords
thyroid
histone deacetylase
cell
agent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02718823A
Other languages
German (de)
English (en)
Inventor
Antonio Tito Fojo
Susan Elaine Bates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP1356053A2 publication Critical patent/EP1356053A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouvelles approches du traitement du cancer de la thyroïde. Ces approches comprennent des méthodes visant à améliorer l'expression génique spécifique à la thyroïde, par exemple des méthodes visant à améliorer l'expression de thyroglobuline et/ou du symporteur de Na<+>/I<-> dans les cellules cancéreuses thyroïdiennes. L'expression améliorée de gènes spécifiques à la thyroïde favorise la différenciation cellulaire et réduit les comportements biologiquement agressifs, tels que l'invasion et la métastase. L'expression améliorée de thyroglobuline et/ou du symporteur de Na<+>/I<-> augmente l'abilité des cellules cancéreuses thyroïdiennes de concentrer l'iode ou l'iodure, ce qui rend les cellules plus sensibles à la thérapie à l'iode radioactive. L'invention concerne également des procédés de détection des néoplasmes de la thyroïde chez un sujet, par l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de l'histone déacétylase, l'administration d'un agent détectable dont l'absorption ou la concentration dans les cellules thyroïdiennes est augmentée par l'administration de l'inhibiteur de l'histone déacétylase, et la détection de l'agent détectable.
EP02718823A 2001-01-10 2002-01-09 Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide Withdrawn EP1356053A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26073301P 2001-01-10 2001-01-10
US260733P 2001-01-10
PCT/US2002/000714 WO2002055688A2 (fr) 2001-01-10 2002-01-09 Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide

Publications (1)

Publication Number Publication Date
EP1356053A2 true EP1356053A2 (fr) 2003-10-29

Family

ID=22990378

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02718823A Withdrawn EP1356053A2 (fr) 2001-01-10 2002-01-09 Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide

Country Status (5)

Country Link
EP (1) EP1356053A2 (fr)
JP (1) JP2005507231A (fr)
AU (1) AU2002249938B2 (fr)
CA (1) CA2434269A1 (fr)
WO (1) WO2002055688A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10227136A1 (de) * 2002-06-18 2004-01-29 Loos, Ulrich, Prof. Dr.med. Thiazolidindione enthaltende Zusammensetzungen und deren Verwendung
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
CA2518318A1 (fr) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
EP1824831A2 (fr) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
EP1996233A2 (fr) * 2006-02-27 2008-12-03 Gilead Colorado, Inc. Combinaisons thérapeutiques et méthodes pour amélioration cardio-vasculaire et traitement de maladie cardio-vasculaire
EP2049139A4 (fr) 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc Traitement de tumeurs exprimant ras
WO2007146730A2 (fr) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Thérapie à base d'inhibiteurs de désacétylase (dac)
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
EP2102230A2 (fr) 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Préparation de la romidepsine
AU2011279303B2 (en) 2010-07-12 2015-07-16 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500052A (ja) * 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02055688A2 *

Also Published As

Publication number Publication date
JP2005507231A (ja) 2005-03-17
WO2002055688A8 (fr) 2003-09-25
CA2434269A1 (fr) 2002-07-18
WO2002055688A3 (fr) 2003-04-10
AU2002249938B2 (en) 2006-12-21
WO2002055688A2 (fr) 2002-07-18

Similar Documents

Publication Publication Date Title
AU2002249938B2 (en) Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
AU2002249938A1 (en) Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
Kopp et al. Werner & Ingbar’s the Thyroid: A Fundamental and Clinical Text
US20040132643A1 (en) Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
Dadachova et al. The Na+/I− symporter (NIS): imaging and therapeutic applications
Portulano et al. The Na+/I− symporter (NIS): mechanism and medical impact
Furuya et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin
Riesco-Eizaguirre et al. A perspective view of sodium iodide symporter research and its clinical implications
Dohán et al. Advances in Na+/I− symporter (NIS) research in the thyroid and beyond
US20030190319A1 (en) Antibodies specific for CD44v6
AU2016369612A1 (en) Polynucleotides encoding methylmalonyl-CoA mutase
Carvalho et al. The importance of sodium/iodide symporter (NIS) for thyroid cancer management
CN114364704B (zh) 修饰的piggybac转座酶多肽、编码其的多核苷酸、引入载体、试剂盒、将靶序列整合到细胞基因组中的方法以及生产细胞的方法
Cho A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy
EP1397387A1 (fr) Anticorps specifiques contre cd44v6
Matsumoto et al. Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase
Chung et al. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma
Baker et al. The sodium-iodide symporter
WO2000067762A2 (fr) Promedicaments contenant du selenium en tant que therapie du cancer
Presta et al. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene
Min et al. In vitro and in vivo characteristics of a human colon cancer cell line, SNU-C5N, expressing sodium-iodide symporter
Riesco-Eizaguirre et al. Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach
KR20230131178A (ko) 변형된 엔도뉴클레아제를 사용한 유전자 편집
US20040014187A1 (en) Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy
Welsh et al. Stimulation of growth hormone synthesis by glucose in islets of Langerhans isolated from transgenic mice.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030811

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20060130

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

18D Application deemed to be withdrawn

Effective date: 20110801